(Q28191802)

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

1 reference

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Fibrinogen and diabetes mellitus: is it time for intervention trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Evidence for a hyperglycaemia-dependent decrease of antithrombin III-thrombin complex formation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Aspirin therapy in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Platelet adhesion and aggregation in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Induced basal normoglycemia and altered platelet aggregation in non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effect of metabolic control with insulin on plasma von Willebrand factor activity (VIIIR:WF) in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Reduction of platelet aggregation induced by euglycaemic insulin clamp

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Hemostatic alterations with exercise conditioning in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Gemfibrozil treatment of hypertriglyceridemia: improvement on fibrinolysis without change of insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Release of Platelet Plasminogen Activator Inhibitor 1 in Whole Blood Is Increased in Patients With Type II Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Platelet plasminogen activator inhibitor 1 in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Lack of effect of gliclazide on platelet aggregation in insulin-treated and non-insulin-treated diabetes: a two-year controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Dietary regulation of fibrinolytic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Hypertriglyceridemia and regulation of fibrinolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effect of insulin versus sulfonylurea therapy on cardiovascular risk factors and fibrinolysis in type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Increased Platelet Aggregation in Early Diabetus Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Hypertriglyceridaemia and hypercoagulability

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

The role of platelets in diabetes-related vascular complications

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Final report on the aspirin component of the ongoing Physicians' Health Study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Ticlopidine Treatment Reduces the Progression of Nonproliferative Diabetic Retinopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Platelets in diabetes: the role in the hemostatic regulation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021

Which diabetic patients should be taking aspirin?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970225-5

7 January 2021